Lantern Pharma Stock Performance
LTRN Stock | USD 5.38 0.39 6.76% |
On a scale of 0 to 100, Lantern Pharma holds a performance score of 6. The company secures a Beta (Market Risk) of 1.47, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Lantern Pharma will likely underperform. Please check Lantern Pharma's expected short fall, and the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether Lantern Pharma's current price movements will revert.
Risk-Adjusted Performance
6 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Lantern Pharma are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Lantern Pharma displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 2.6 | Five Day Return (0.90) | Year To Date Return 32.37 | Ten Year Return (63.08) | All Time Return (63.08) |
1 | Lantern Pharma Inc. Major Shareholder Aaron G.L. Fletcher Sells 74,297 Shares | 03/01/2024 |
2 | Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating Financial Results on March 18th, 2024 at 430 p.m. ET | 03/11/2024 |
3 | Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284 | 03/15/2024 |
4 | Lantern Pharma Reports Fourth Quarter Fiscal Year 2023 Financial Results and Business Highlights | 03/18/2024 |
5 | LTRN 2023 Results | 03/19/2024 |
6 | Lantern Pharma Inc. Expected to Earn Q1 2024 Earnings of Per Share - Defense World | 03/20/2024 |
7 | Is Lantern Pharma Inc Stock a Smart Investment Tuesday - InvestorsObserver | 03/26/2024 |
8 | Lantern Pharma Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan | 04/22/2024 |
9 | Lantern Pharma Launches Webinar Wednesdays Featuring World-Class Physician Scientists Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development | 04/24/2024 |
Begin Period Cash Flow | 37.7 M |
Lantern |
Lantern Pharma Relative Risk vs. Return Landscape
If you would invest 429.00 in Lantern Pharma on January 26, 2024 and sell it today you would earn a total of 109.00 from holding Lantern Pharma or generate 25.41% return on investment over 90 days. Lantern Pharma is currently generating 0.8442% in daily expected returns and assumes 9.8615% risk (volatility on return distribution) over the 90 days horizon. In different words, 87% of stocks are less volatile than Lantern, and 84% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Lantern Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lantern Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lantern Pharma, and traders can use it to determine the average amount a Lantern Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0856
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | LTRN | |||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns |
Estimated Market Risk
9.86 actual daily | 87 87% of assets are less volatile |
Expected Return
0.84 actual daily | 16 84% of assets have higher returns |
Risk-Adjusted Return
0.09 actual daily | 6 94% of assets perform better |
Based on monthly moving average Lantern Pharma is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lantern Pharma by adding it to a well-diversified portfolio.
Lantern Pharma Fundamentals Growth
Lantern Stock prices reflect investors' perceptions of the future prospects and financial health of Lantern Pharma, and Lantern Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lantern Stock performance.
Return On Equity | -0.33 | ||||
Return On Asset | -0.22 | ||||
Current Valuation | 16.72 M | ||||
Shares Outstanding | 10.74 M | ||||
Price To Book | 1.68 X | ||||
EBITDA | (17.7 M) | ||||
Net Income | (15.96 M) | ||||
Cash And Equivalents | 62.15 M | ||||
Cash Per Share | 5.74 X | ||||
Total Debt | 234.47 K | ||||
Debt To Equity | 0 % | ||||
Current Ratio | 12.38 X | ||||
Book Value Per Share | 3.82 X | ||||
Cash Flow From Operations | (14.35 M) | ||||
Earnings Per Share | (1.47) X | ||||
Market Capitalization | 57.79 M | ||||
Total Asset | 43.65 M | ||||
Retained Earnings | (55.24 M) | ||||
Working Capital | 40.66 M | ||||
About Lantern Pharma Performance
To evaluate Lantern Pharma Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Lantern Pharma generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Lantern Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Lantern Pharma market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Lantern's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for Next Year | ||
Days Of Inventory On Hand | -1.6 K | -1.7 K | |
Return On Tangible Assets | (0.37) | (0.38) | |
Return On Capital Employed | (0.44) | (0.41) | |
Return On Assets | (0.37) | (0.38) | |
Return On Equity | (0.39) | (0.37) |
Things to note about Lantern Pharma performance evaluation
Checking the ongoing alerts about Lantern Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lantern Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Lantern Pharma is way too risky over 90 days horizon | |
Lantern Pharma appears to be risky and price may revert if volatility continues | |
Lantern Pharma has high likelihood to experience some financial distress in the next 2 years | |
Net Loss for the year was (15.96 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Lantern Pharma currently holds about 62.15 M in cash with (14.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.74, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Lantern Pharma has a frail financial position based on the latest SEC disclosures | |
Roughly 15.0% of the company outstanding shares are owned by corporate insiders | |
Latest headline from businesswire.com: Lantern Pharma Launches Webinar Wednesdays Featuring World-Class Physician Scientists Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development |
- Analyzing Lantern Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lantern Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Lantern Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lantern Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lantern Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lantern Pharma's stock. These opinions can provide insight into Lantern Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Complementary Tools for Lantern Stock analysis
When running Lantern Pharma's price analysis, check to measure Lantern Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lantern Pharma is operating at the current time. Most of Lantern Pharma's value examination focuses on studying past and present price action to predict the probability of Lantern Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lantern Pharma's price. Additionally, you may evaluate how the addition of Lantern Pharma to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is Lantern Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.47) | Return On Assets (0.22) | Return On Equity (0.33) |
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.